Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $85

Benzinga · 05/09 18:45
Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $90 to $85.